Skip to main content
. 2019 Sep 30;9(3):120–126. doi: 10.4103/IJCIIS.IJCIIS_40_19

Table 1.

Characteristics of the present study

Variables Control (n=25) T2DM (n=80) P
Age (years) 43.98±3.21 44.71±3.63 0.33
Body weight (kg) 81.77±8.83 99.85±9.53 0.0001
Height (m) 179.77±3.88 179.34±3.21 0.57
Concurrent diseases
 Hypertension 0 69 (86.25)
 Dyslipidemia 0 77 (96.25)
 Peripheral vascular diseases 0 11 (13.75)
 Asthma 0 5 (6.25)
 COPD 0 9 (11.25)
 IHD 0 75 (93.75)
Current therapy
 Metformin 0 29 (36.25)
 Glyburide 0 30 (37.5)
 Metformin + glyburide 0 21 (26.25)
Other drugs
 Statins 0 78 (97.5)
 Omega-3 fatty acid 0 73 (91.25)
 Antiplatelets 0 74 (92.5)
 Anticoagulants 0 5 (6.25)
 Theophylline 0 9 (11.25)
 ACEI 0 44 (55)
 CCBs 0 12 (15)
 Trimetazidine 0 39 (48.75)
 Tonics 6 (7.5) 72 (90) 0.0001

Data are expressed as mean±SD, n (%), unpaired t-test was used. BMI: Body mass index, WHR: Waist-hip ratio, COPD: Chronic obstructive pulmonary disease, IHD: Ischemic heart disease, ACEI: Angiotensin converting enzyme inhibitor, CCBs: Calcium channel blockers, T2DM: Type 2 diabetes mellitus, SD: Standard deviation